Neovasc Inc. (NVCN): Price and Financial Metrics

Neovasc Inc. (NVCN): $28.38

0.24 (+0.85%)

POWR Rating

Component Grades













NVCN Stock Summary

  • NEOVASC INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 13.21% of US listed stocks.
  • With a price/sales ratio of 24.84, NEOVASC INC has a higher such ratio than 94.76% of stocks in our set.
  • The volatility of NEOVASC INC's share price is greater than that of 96.97% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to NEOVASC INC, a group of peers worth examining would be ONTX, KOPN, XBIO, BYSI, and HCWB.
  • NVCN's SEC filings can be seen here. And to visit NEOVASC INC's official web site, go to

NVCN Valuation Summary

  • NVCN's EV/EBIT ratio is -1.8; this is 117.73% lower than that of the median Healthcare stock.
  • Over the past 184 months, NVCN's price/sales ratio has gone up 23.4.

Below are key valuation metrics over time for NVCN.

Stock Date P/S P/B P/E EV/EBIT
NVCN 2023-01-30 24.5 2.7 -2.3 -1.8
NVCN 2023-01-27 24.5 2.7 -2.3 -1.8
NVCN 2023-01-26 24.6 2.7 -2.3 -1.8
NVCN 2023-01-25 24.5 2.7 -2.3 -1.8
NVCN 2023-01-24 24.5 2.7 -2.3 -1.8
NVCN 2023-01-23 24.4 2.7 -2.3 -1.8

NVCN Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at 30.18%.
  • The 3 year net cashflow from operations growth rate now stands at -6.79%.
  • Its 5 year net income to common stockholders growth rate is now at 63.3%.
Over the past 37 months, NVCN's revenue has gone up $1,061,607.

The table below shows NVCN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.111242 -23.9265 -33.51675
2022-06-30 2.891351 -24.98559 -32.82565
2022-03-31 2.706359 -25.43355 -32.88106
2021-12-31 2.547406 -27.11277 -24.88907
2021-09-30 2.302284 -29.37562 -23.15948
2021-06-30 2.225282 -30.89349 -25.85856

NVCN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVCN has a Quality Grade of F, ranking ahead of 0.31% of graded US stocks.
  • NVCN's asset turnover comes in at 0.14 -- ranking 148th of 184 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows NVCN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.140 0.772 -4.860
2019-12-31 0.189 0.781 -4.740
2018-12-31 0.102 0.791 -28.053
2017-12-31 0.089 0.355 0.408
2016-12-31 0.119 0.255 1.637
2015-12-31 0.234 0.301 -3.837

NVCN Price Target

For more insight on analysts targets of NVCN, see our NVCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.50 Average Broker Recommendation 1.5 (Moderate Buy)

NVCN Stock Price Chart Interactive Chart >

Price chart for NVCN

NVCN Price/Volume Stats

Current price $28.38 52-week high $28.43
Prev. close $28.14 52-week low $4.59
Day low $28.02 Volume 31,200
Day high $28.43 Avg. volume 98,881
50-day MA $17.96 Dividend yield N/A
200-day MA $9.42 Market Cap 77.85M

Neovasc Inc. (NVCN) Company Bio

Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The Company also sells a line of biological tissue products that are used as components in third-party medical products including transcatheter heart valves. The company was founded in 2000 and is based in Richmond, Canada.

NVCN Latest News Stream

Event/Time News Detail
Loading, please wait...

NVCN Latest Social Stream

Loading social stream, please wait...

View Full NVCN Social Stream

Latest NVCN News From Around the Web

Below are the latest news stories about NEOVASC INC that investors may wish to consider to help them evaluate NVCN as an investment opportunity.

Neovasc Announces German Reimbursement Renewal

VANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New examination and treatment methods (NUBs) are comprised of novel and innovative medicines, medical products and procedure

Yahoo | February 1, 2023

5 big deal reports: Sun Pharma’s $576M pact for Concert Pharma

By Davit Kirakosyan

Yahoo | January 22, 2023

Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome

Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.

Yahoo | January 18, 2023

Dow Dinged As Big Bank Earnings Weigh

A round of earnings from the banking sector is weighing today, stifling Wall Street's early 2023 momentum. | January 17, 2023

Shockwave Medical Seeks To Bolster Its Cardiovascular Disease Portfolio With Neovasc Acquisition

Shockwave Medical Inc (NASDAQ: SWAV) has agreed to acquire Neovasc Inc (NASDAQ: NVCN) for an upfront cash payment of $27.25 per share, corresponding to an enterprise value of approximately $100 million. The upfront cash consideration represents a 27% and 68% premium to the closing price and 30-day VWAP, respectively, of Neovasc's common shares on Jan. 13, 2023. Neovasc shareholders will also receive a potential deferred payment in the form of a non-tradable contingent value right (CVR), entitlin

Yahoo | January 17, 2023

Read More 'NVCN' Stories Here

NVCN Price Returns

1-mo 53.57%
3-mo 335.94%
6-mo 261.99%
1-year 142.00%
3-year -52.30%
5-year -99.67%
YTD 79.68%
2022 34.83%
2021 -50.76%
2020 -82.41%
2019 -9.83%
2018 -99.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8793 seconds.